Bivalirudin in percutaneous coronary intervention

References

• AllieDEHebertCJLirtzmanMDA safety and feasibility report of combined direct thrombin and GP IIb/IIIa inhibition with bivalirudin and tirofiban in peripheral vascular disease intervention: treating critical limb ischemia like acute coronary syndromeJ Invasive Cardiol20051742743216079449
   PubMedGoogle Scholar
• AndersenDLGreenberg, FujikawaKProtease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activityProc Nat. Acad Sci U S A1999961118993
   PubMed Web of Science ®Google Scholar
• AntmanEMMcCabeCHBraunwaldEBivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial. The Thrombolysis in Myocardial InfarctionAm Heart J20021432293411835024
   PubMed Web of Science ®Google Scholar
• BatesSMWeitzJIThe mechanism of action of thrombin inhibitorsJ Invasive Cardiol200012Suppl FF2732
   PubMedGoogle Scholar
• BeckerRCUnderstanding the dynamics of thrombin in cardiovascular disease: pathobiology and biochemistry for the clinicianAm Heart J2005149Suppl1S2815644790
   PubMedGoogle Scholar
• BittlJAChaitmenBRFeitFBivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty StudyAm Heart J20011429525911717596
   PubMed Web of Science ®Google Scholar
• BittlJAStronyJBrinkerJATreatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study InvestigatorsN Engl J Med19953337647697643883
   PubMed Web of Science ®Google Scholar
• BrenerSJMoliternoDJLincoffAMRelationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary interventionCirculation2004110994815302778
   PubMed Web of Science ®Google Scholar
• CheneauECanosDKuchulakantiPKValue of monitoring activated clotting time when bivalirudin is used as the sole anticoagulation agent for percutaneous coronary interventionAm J Cardiol2004947899215374791
   PubMedGoogle Scholar
• ChewDPBhattDLKimballWBivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trialsAm J Cardiol2003929192314556866
   PubMed Web of Science ®Google Scholar
• ChewDPLincoffAMGurmHBivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial)Am J Cardiol200595581515721095
   PubMed Web of Science ®Google Scholar
• ChongBHHeparin-induced thrombocytopeniaJ Thromb Haemost200311471812871282
   PubMed Web of Science ®Google Scholar
• CohenDJLincoffAMLavelleTAEconomic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trialJ Am Coll Cardiol200444179280015519009
   PubMed Web of Science ®Google Scholar
• DangasGLasicZMehranREffectiveness of the concomitant use of bivalirudin and drug-eluting stents (from the prospective, multicenter BivAlirudin and Drug-Eluting STents [ADEST] study)Am J Cardiol2005966596316125490
   PubMed Web of Science ®Google Scholar
• De CandiaEHallSWRutellaSBinding of thrombin to glycoprotein Ib accelerates the hydrolysis of Par-1 on intact plateletsJ Biol Chem200127646929811084032
   PubMed Web of Science ®Google Scholar
• Direct Thrombin Inhibitor Trialists’ Collaborative GroupDirect thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients’ dataLancet200235929430211830196
   PubMed Web of Science ®Google Scholar
• EbrahimiRLincoffAMBittlJABivalirudin vs Heparin in Percutaneous Coronary Intervention: A Pooled AnalysisJ Cardiovasc Pharmacol Ther2005102091616382257
   PubMed Web of Science ®Google Scholar
• EitzmanDTChiLSagginLHeparin neutralization by platelet-rich thrombi. Role of platelet factor 4Circulation199489152398149517
   PubMed Web of Science ®Google Scholar
• GibsonCMMorrowDAMurphySAA randomized trial to evaluate the relative protection against post-PCI microvascular dysfunction, ischaemia and inflammation among anti-platelet and antithrombotic agents: the PROTECT-TIMI 30 TrialJ Am Coll Cardiol20064723647316781360
   PubMed Web of Science ®Google Scholar
• KuchulakantiPWolframRTorgusonRBivalirudin compared with IIb/IIIa inhibitors in patients with in-stent restenosis undergoing intracoronary brachytherapyCardiovasc Revasc Med20056154916326376
   PubMedGoogle Scholar
• LincoffAMBittlJAHarringtonRABivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trialJAMA20032898536312588269
   PubMed Web of Science ®Google Scholar
• LincoffAMBittlJAKleimanNSComparison of Bivalirudin Versus Heparin During Percutaneous Coronary Intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 TrialAm J Cardiol2004b931092615110198
   PubMed Web of Science ®Google Scholar
• LincoffAMKleimanNSKereiakesDJLong-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trialJAMA2004a29269670315304466
   PubMed Web of Science ®Google Scholar
• LincoffAMKleimanNSKottke-MarchantKBivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET)Am Heart J20021438475312040347
   PubMed Web of Science ®Google Scholar
• MacFarlaneRGAn enzymatic cascade in the blood clotting mechanism, and its function as a biological amplifierNature1964202498-99.14167839
   PubMed Web of Science ®Google Scholar
• MahaffeyKWLewisBEWildermannNMThe anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main resultsJ Invasive Cardiol200315611614608128
   PubMedGoogle Scholar
• MaraganoreJMBourdonPJablonskiJDesign and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombinBiochemistry19902970951012223763
   PubMed Web of Science ®Google Scholar
• ParryMAMaraganoreJMStoneSRKinetic mechanism for the interaction of Hirulog with thrombinBiochemistry19943314807147993908
   PubMed Web of Science ®Google Scholar
• ReedMDBellDClinical pharmacology of bivalirudinPharmacotherapy200222S10511
   PubMed Web of Science ®Google Scholar
• RobsonRWhiteHAylwardPBivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and genderClin Pharmacol Ther200271433912087346
   PubMed Web of Science ®Google Scholar
• SarichTCWolztMErikssonUGEffects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjectsJ Am Coll Cardiol2003415576412598065
   PubMed Web of Science ®Google Scholar
• SawJLincoffAMDeSmetWLack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudyJ Am Coll Cardiol2004441194915364319
   PubMed Web of Science ®Google Scholar
• SchusslerJMCameronCSAzamAEffect of bivalirudin on length of stay in the recovery area after percutaneous coronary intervention compared with heparin alone, heparin + abciximab, or heparin + eptifibatideAm J Cardiol20049414171915566915
   PubMedGoogle Scholar
• SmithSCFeldmanTEHirshfeldJWACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention [online]2005 Accessed 25 Sept 2006. URL: http://www.acc.org
   Google Scholar
• SoslauGClassRMorganDAUnique pathway of thrombin-induced platelet aggregation mediated by glycoprotein IbJ Biol Chem2001276211738311283012
   PubMed Web of Science ®Google Scholar
• StoneGWBertrandMColomboAAcute catheterization and urgent Intervention triage strategy (ACUITY) trial: study design and rationaleAm Heart J20041487647515523305
   PubMed Web of Science ®Google Scholar
• StoneGWProspective, Randomized Comparison of Heparin Plus IIb/IIIa Inhibition and Bivalirudin With or Without IIb/IIIa Inhibition in Patients With Acute Coronary Syndromes: The ACUITY Trial2006a American College of Cardiology Scientific Sessions 2006. Late Breaking Clinical Trials Session I
   Google Scholar
• StoneGWProspective, Randomized Comparison of Routine Upfront Initiation Versus Selective Use of Glycoprotein IIb/IIIa Inhibitors in Patients With Acute Coronary Syndromes: The ACUITY Timing Trial2006b i2 Summit 2006 Late-Breaking Clinical Trials II
   Google Scholar
• TulinskyAMolecular interactions of thrombinSemin Thromb Hemost199622117248807707
   PubMed Web of Science ®Google Scholar
• WeitzJIHudobaMMasselDClot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitorsJ Clin Invest199086385912384594
   PubMed Web of Science ®Google Scholar
• WeitzJILeslieBHudobaMThrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitorsCirculation199897544529494024
   PubMed Web of Science ®Google Scholar
• WhiteCMThrombin-directed inhibitors: pharmacology and clinical useAm Heart J2005149S546015644794
   PubMed Web of Science ®Google Scholar
• WhiteHThrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trialLancet2001358929618556311741625
   PubMed Web of Science ®Google Scholar
• XiaoZTherouxPPlatelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitorCirculation19989725169462526
   PubMed Web of Science ®Google Scholar